New “Blue Light” System Targets Detection of Bladder Cancer

Karl Storz has debuted its Blue Light Cystoscopy with Cysview at a major U.S. healthcare improvement conference. The system uses KARL STORZ Photodynamic Diagnosis (PDD) technology, and is aimed at early detection of non-muscle invasive bladder cancer (NMIBC).


The KARL STORZ  (PDD) System – Blue Light Cystoscopy with Cysview (BLCC) is one of the medical innovations that was showcased in front of thousands of healthcare providers at Premier Inc.’s 2017 Breakthroughs Conference and Exhibition on June 27.

Premier Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,750 U.S. hospitals and more than 130,000 other provider organizations. Its conference recognizes advances in healthcare while highlighting industry suppliers committed to innovation and improving patient outcomes.

The KARL STORZ PDD system enhances detection and treatment of NMIBC. The PDD system uses a photosensitive marker, which is introduced into the bladder, absorbed and converted into a pigment that is deposited into cancerous tissue.

At the heart of this system is the KARL STORZ D-LIGHT C light source as well as specially adapted telescopes. Under blue light excitation, this pigment emits red fluorescence while normal tissue appears dark blue. This helps the physician to clearly identify tumorous tissue. It is the only FDA-approved technology that is clinically proven to detect more Ta/T1 bladder cancer lesions vs. white-light cystoscopy alone, and promote a more comprehensive tumor resection. BLCC is recommended to decrease recurrence of bladder cancer and avoid complications associated with TURBT.


“KARL STORZ shares Premier’s commitment to providing valuable products to our alliance members that are safe, high-quality and cost-effective,” said Durral R. Gilbert, president of supply chain services, Premier. “We believe these innovations can benefit providers as they work to transform healthcare.”

“Use of BLCC offers significant new diagnostic and treatment capabilities to Healthcare providers striving to offer state-of-the-art care to their patients and promoting improved clinical outcomes,” says Les Friend, Executive Director, Corporate Accounts, KARL STORZ. “In fact, the American Urological Association and Society for Urologic Oncology included Blue Light Cystoscopy in the 2016 Guidelines for the management of NMIBC.”

He adds, “We consider it an honor to support the world-class level of care and treatment that the Clinical teams offer to their patients and to showcase this technology as one of the 2017 Masters of Innovation.”


Source: Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *